

Expanding the Therapeutic Landscape of Advanced NSCLC Targeting HER2 CME

9 SEPTEMBER 2019

TIME: 7:00 AM – 8:00 AM

VENUE: FIRA DE BARCELONA, GRAN VIA, HALL 8, NORTH ACCESS | ROOM: HILTON HEAD (1978)

www.medscape.org/sympo/her2-nsclc-registration

Medscape®
LIVE!

MODERATOR



Maurice Perol, MD
Centre Leon Berard
Medical Director of Thoracic
Oncology Program
Leon Berard Cancer Center
Lyon, France

PANELISTS



Hossein Borghaei, MD
Professor and Chief
Division of Thoracic Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania
United States



Shirish Gadgeel, MD
Professor, Division of
Hematology & Oncology,
Department of Internal Medicine,
Rogel Cancer Center, University
of Michigan
Ann Arbor, Michigan
United States

AGENDA

7:00 AM

Welcome and Introduction

7:05 AM

*When and How Can HER2
Be Tested in Patients With
Advanced NSCLC?*

7:20 AM

*Progression After First-Line
EGFR TKI: A Patient With a
HER2 Mutation*

7:35 AM

*Future Therapeutic
Landscape for HER2
Dysregulation*

7:50 AM

*Panel Discussion and
Audience Questions*

8:00 AM

Adjournment

TARGET AUDIENCE

This activity is intended for oncologists, pulmonologists, internal medicine physicians, PCPs, and pathologists.

LEARNING OBJECTIVES

Upon completion of this activity, participants will:

Have increased knowledge regarding the

- Human epidermal growth factor receptor 2 (HER2) testing in non-small lung cancer (NSCLC)
- HER2-directed therapies in development for the management of patients with advanced NSCLC
- Most recent efficacy and safety data from clinical trials with HER2-directed therapies

Demonstrate greater confidence in their ability to

- Know the potential therapeutic role and place of new HER2-directed therapies in the treatment algorithm of advanced NSCLC

ACCREDITATION STATEMENT

Medscape



JOINTLY ACCREDITED PROVIDER
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

FOR PHYSICIANS

Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program was approved by the IASLC 2019 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2019 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.



www.medscape.org/sympo/her2-nsclc-registration